News roundup: stroke rehab uses Hollywood technology, 3M sues IBM Watson Health on analytics software misuse, AI-based skin cancer detection apps fail, Dictum’s successful telemed use post-pediatric surgery, malware attacks Boston practice network

February 14, 2020 | by

Motion capture technology being used in stroke and TBI rehab. Best known for turning actors into cartoon superheroes, motion capture tech is now being used at Spaulding Rehabilitation Hospital in Boston for returning mobility to stroke and TBI patients. Attached to the patient are sensors–reflective markers–on key parts of the body. Using an array of infrared cameras, the patient is tracked on gait and other affected motion areas. Doctors and therapists can then better target therapy, plus assistive technologies from orthotics to full exoskeletons. Includes video. STAT

When Giants Sue. 3M is suing IBM Watson Health on their use of licensed 3M software in ‘unauthorized ways’ and charging direct copyright infringement and contract breaches. 3M’s Grouper Plus System analyzes claims and other coded data to help calculate reimbursement. 3M contends that IBM was licensed only for internal use dating back to a Truven agreement in 2007, years before their acquisition by IBM. The suit also adds that IBM then integrated the software into Watson platforms without a license transfer and expansion to cover the use, as well as dodged an audit of the use. The suit is in NY Federal Court. Becker’s Health IT Report

Algorithm-based dermatology apps fail to accurately detect risk for melanomas and similar skin cancer.  A just-published BMJ study determined that these smartphone apps, which use algorithms that catalogue and classify images of lesions into high or low risk for skin cancer and return an immediate risk assessment with subsequent recommendation to the user, are not effective. Six apps were examined, including two with a CE mark. None were FDA-approved and two were cited by the Federal Trade Commission for deceptive marketing. Only one, SkinVision, is still commercially available. Study results do not apply to apps that physicians use in direct telemedicine consults. IEEE Spectrum

Successful test and planned rollout of telemedicine tablet for post-surgery checks at Children’s Hospital of Richmond (Virginia–CHoR). The Dictum Health eVER-HOME tablet used for virtual visits had a 92 percent acceptance rate of telemedicine visits in place of in-person visits, zero return to hospital/ER events, earlier patient discharge post-surgery (12 to 24 hours), and avoidance of long-distance travel by patients for follow-up visits, a significant factor as CHoR is a destination hospital for specialized pediatric surgery. The rollout will include AI capabilities in Dictum’s Care Central platform to help determine rising risk and more. Dictum Health is a company best known for telemedicine units for remote workers (e.g. oil rigs) using their Virtual Exam Room (VER) technologies. Dictum release, mHealth Intelligence

CHoR is having a better week than a physician’s network affiliated with Boston Children’s Hospital. Pediatric Physician’s Organization at Children’s (PPOC) is the victim of a malware attack affecting computer systems at about 500 affiliated physicians and clinicians. The impacted systems have been quarantined and does not affect BCH. Becker’s Hospital Review, Health IT Security  Health IT Security also rounds up other recent data breaches, hacks, and phishing attacks.

Coffee break reading: a ‘thumbs down’ on IBM Watson Health from IEEE Spectrum and ‘Der Spiegel’

August 9, 2018 | by

In a few short years (2012 to now), IBM Watson Health has gone from being a 9,000 lb Harbinger of the Future to a Flopping Flounder. It was first MD Anderson Cancer Center at the University of Texas last year [TTA 22 Feb 17] kicking Watson to the curb after spending $62 million, then all these machine learning, blockchain, and AI upstarts doing most of what Watson was going to do, but cheaper and faster, which this Editor observed early on [TTA 3 Feb 17]. At the end of May, IBM laid off hundreds of workers primarily at three recently acquired data analytics companies. All came on board as market leaders with significant books of business: Phytel, Explorys, and Truven. Clients have evaporated; Phytel, before the acquisition ranked #1 by KLAS in analytics for its patient communication system, reportedly went from 150 to 80 clients. IBM denies the layoffs were anything but much-needed post-acquisition restructuring and refocusing on high-value segments of the IT market.

IEEE Spectrum rated the causes as corporate mismanagement (mashing Phytel and Explorys; IBM’s ‘bluewashing’ acquired companies; the inept ‘offering management’ product development process; the crushed innovation) plus inroads made by competition (those upstarts again!). What’s unusual is the sourcing from former engineers–IEEE is the trade group for tech and engineering professionals. The former IBM-ers were willing to talk in detail and depth, albeit anonymously. 

Der Spiegel takes the German and clinical perspective of what IBM Watson Health has gone wrong, starting with the well-documented failures of Watson at hospitals in Marburg and Giessen. The CEO of Rhön-Klinikum AG, which owns the university hospital at Marburg, reviewed it in action in February. “The performance was unacceptable — the medical understanding at IBM just wasn’t there.” It stumbled over and past diagnoses even a first-year resident would have considered. The test at Marburg ended before a single patient was treated.

The article also outlines several reasons why, including that Watson, after all this time, still has trouble crunching real doctor and physical data. It does not comprehend physician shorthand and negation language, which this Editor imagines is multiplied in languages other than American English. “Some are even questioning whether Watson is more of a marketing bluff by IBM than a crowning achievement in the world of artificial intelligence.” More scathingly, the Rhön-Klinikum AG CEO: “IBM acted as if it had reinvented medicine from scratch. In reality, they were all gloss and didn’t have a plan. Our experts had to take them by the hand.”

Hardly The Blue Wave of the Future. Perhaps the analogy is Dr. Watson as The Great Oz.

Was 2016 a great or off year for digital health funding, M&A, IPOs? (updated)

January 10, 2017 | by

It depends on the study you read and how jaundiced your view is. If you believe the StartUp Health Insights 2016 ‘Health Moonshots’ report, 2016 digital health funding has hit a zenith of $8.18 bn (up 38 percent from 2015), with 500 companies enjoying funding from over 900 individual investors. Yet over at fellow funder Rock Health, the forecast is far more circumspect. They tracked only half the funding–$4.2 bn in funding–with 296 deals and 451 investors, down from the $4.6 bn over 276 deals in 2015.

There are significant differences in methodology. Rock Health tracks deals only over $2 million in value, while StartUp Health seems to have no minimum or maximum; the latter includes early stage deals at a lower value (their cross-section of ~$1 million deals has 15). StartUp Health gathers in international deals at all levels (pages 11-12),  whereas Rock Health only includes US-funded ventures. Another observation is that StartUp Health defines ‘digital health’ differently than Rock Health, most notably in ‘patient/consumer experience’, ‘wellness’ and ‘personalized health’. This can be seen by comparing their top 10 categories and total funding: (more…)